Lipid Sciences, Inc., (LIPD) announced that with the recent completion of successful studies in a mouse animal model, it has achieved an important development milestone.
The HIV/AIDS epidemic continues its devastating march across the globe, with more deaths and infections this year than ever before, according to a U.N. report.
"The prospective, multicenter cohort study EuroSIDA has previously reported on predictors and outcomes of anemia in patients infected with human immunodeficiency virus," scientistsin Denmark noted. "In a Cox proportional-hazards model with serial measures of CD4+ cell count, plasma viral load, and degrees of anemia fitted as time-dependent variables, the relative hazard of death increased markedly for patients with anemia versus no anemia."
The number of AIDS patients in China is reaching "frightening" levels, a renowned expert on the disease said, after Beijing said it would provide free treatment to thousands of sufferers in dire financial straits.
Data from national surveys conducted in the United States from 1987-2002 indicate that adolescents and adults in certain populations remain at high risk for transmitting or acquiring HIV infection.
Increases in high-density lipoprotein cholesterol (HDL-C) - so-called "good" cholesterol - were observed at 48 weeks among patients participating in a phase III clinical trial of the new protease inhibitor (PI) Lexiva (fosamprenavir calcium) (formerly GW43908, or 908) boosted with ritonavir (Lexiva/r), according to research presented at the meeting of the European AIDS Council (EAC).
In its latest attempt to reduce the number of new HIV infections nationwide, the U.S. government is locating prevention programs squarely in the treatment setting.
The rapid spread of AIDS in China and India could destroy any chance of containing the disease, U.S. Health and Human Services Secretary Tommy Thompson warned.
Questions have arisen recently over whether the HIV virus can or cannot pass through pores in latex condoms. European Union (E.U.) research projects provide extensive proof that this is not the case: if properly used, condoms are safe.
"Protease inhibitor-based highly active antiretroviral therapy (PI-HAART) has been implicated in dyslipidemia, peripheral insulin resistance, and abnormal adipose tissue deposition in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome, or AIDS," scientists in St. Louis explained. "In vitro evidence indicates that some PIs reduce adipocyte lipoprotein (LPL) and hepatic lipase (HL) expression and activities."
University of California San Francisco (UCSF) researchers have been funded by the U.S. National Institutes of Health to study the antiretroviral drug tenofovir as a potential pre-exposure prophylaxis in Cambodia among high-risk, HIV-uninfected women. The research will look at safety and effectiveness of the drug in preventing the acquisition of HIV.
An international study suggests that prognosis for patients with HIV/AIDS might be more reliably determined 6 months after initiation of highly active antiretroviral therapy (HAART), rather than before the start of treatment.
In an effort to slow the spread of AIDS in Asia, the World Health Organization (WHO) recently met in Laos to promote its policy of 100% condom use among sex workers.
Resistance mutations to anti-HIV medications are more likely to occur in patients who take most of their medications rather than in those who don't, according to AIDS specialists at the University of California, San Francisco (UCSF).
The world's first human test of a vaccine against the prevalent subtype of HIV in sub-Saharan African and Asia, where millions have the virus that causes AIDS, is now under way.
AIDS patients with primary central nervous system lymphoma who receive the HAART "cocktail" therapy live much longer than those not treated with the therapy, researchers at UT Southwestern Medical Center at Dallas found.
Researchers in Germany have identified an interferon (IFN) resistance gene whose expression is critical for modified vaccinia virus Ankara (MVA) replication.
A novel adenovirus-based vaccine against the simian version of HIV (SIV) has delivered promising results in a macaque model of infection, researchers in the United States report.
A series of novel anti-HIV antibodies have been identified. "Inhibitory antibodies to the reverse transcriptase (RT) of human immunodeficiency virus type-1 (HIV-1) can be used to block the life cycle of the virus," researchers in Israel explained.
Hollis-Eden Pharmaceuticals, Inc., (HEPH) announced additional data from a phase II clinical trial conducted in South Africa in late-stage HIV patients who have progressed to AIDS (average starting CD4 count for patients in the trial was less than 50).
Reagents based on autologous HIV strain sequences are needed for accurate measurements of antiviral T-cell activity, researchers write in the Journal of Virology
AIDS virus infections among gay men in King County, Washington, appear to be soaring, prompting warnings from health officials to take more precautions against spread of the deadly ailment.
Gay men who have poor communication skills and feel unable to protect themselves against HIV infection are more likely to engage in risky sexual behaviors, according to newly released data.
Given concerns about the potential for adverse effects on unborn and newborn children exposed to prophylactic antiretroviral therapy (ART), researchers said they find data from a large study that indicate no serious adverse events in a large study "reassuring."
A new study by a research scientist at Weill Cornell Medical College has shown that early antiretroviral therapy for individuals with HIV may significantly increase life expectancy, even when accounting for side effects like heightened cholesterol levels. Additionally, early therapy was found to be cost-effective, yet it is still being denied to many patients because of cost.
Researchers at Columbus Children's Hospital and its collaborators, Targeted Genetics Corp. and the International AIDS Vaccine Initiative (IAVI), have demonstrated that utilizing a recombinant adeno-associated virus (rAAV)-based HIV vaccine resulted in robust and sustained antibody and T cell immune responses in nonhuman primates (monkeys).
Immunopathologists from the Pasteur Institute report they've "reconstituted cytomegalovirus (CMV)-specific T-cell responses in human immunodeficiency virus-1 [HIV-1] positive, CMV-positive patients receiving highly active antiretroviral treatment (HAART)."
Data were presented at the 16th International Conference on Antiviral Research that the experimental RNA-based drug Ampligen provides a significant increase in the time interval before HIV rebound that follows cessation of current "cocktails" of anti-HIV drugs (HAART or highly active antiretroviral therapy). The report was presented by Dr. William Mitchell of Vanderbilt University.
Australian researchers have found a drug-resistant strain of the hepatitis B virus (HBV) in a number of hepatitis B and HIV coinfected patients treated with the antiviral agent lamivudine.
The prevalence of visual impairment for patients who have acquired immunodeficiency syndrome (AIDS) and are diagnosed with cytomegalovirus (CMV) retinitis is high, but varies with demographic characteristics, according to new research.
Researchers in the United States have found a way to improve the efficacy of an anti-HIV monoclonal antibody that could serve as the basis for an effective vaccine.
Vaccine researchers in the United States and Thailand have elucidated the HIV-specific T-cell profile in "highly exposed but persistently seronegative" women (HW).
Increased estrogen levels may underlie sexual dysfunction in male HIV patients. According to recent research from Germany, "various endocrine functions have been described" as a result of HIV infection.
The role of DC-SIGN in HIV cell entry varies by cell type. "DC-SIGN (CD209) is a C-type lectin expressed by several groups of dendritic cells (DC), including those derived from blood monocytes and DC found beneath genital epithelium," researchers in New York explained. "DC-SIGN binds the envelope glycoprotein of HIV-1 and facilitates transmission of infectious virus to permissive CD4+ T cells."
Researchers in the United States say that leptin, an appetite-suppressing hormone produced by fat cells, may be involved in the development of HIV-related lipodystrophy.
An alarming number of young gay men appear to be highly anxious and depressed, expressing high levels of self-hatred and low self-esteem, according to new research funded by the ESRC.
Scientists in California have provided the first detailed look at how human antibodies, proteins critical for the body's defense against invading pathogens, may actually drive human immunodeficiency virus (HIV) to mutate and escape detection by the immune system.
A new study used simian immunodeficiency virus (SIV) infection of rhesus monkeys to examine the combined effects of chronic, binge alcohol consumption on the primary stage of SIV/HIV infection. Researchers found that alcohol consumption may increase host susceptibility to SIV/HIV infection.
The unabated flow of illegal drugs from Afghanistan through Central Asia, continuing despite the U.S.-led ousting of the Taliban, is causing rising drug addiction and AIDS infections across the region, a top U.N. drug control official says.
Scientists at the University of Texas Medical Branch at Galveston (UTMB) have identified a crucial link in the process that HIV uses to get inside one kind of human white blood cells.
When AIDS outreach coordinator James Waid begins work with a new client nowadays, the person is often black, female, and heterosexual, rather than white, male, and gay.
Final 48-week results from the NEAT trial, an open-label, multicenter study evaluating the safety and efficacy of the investigational protease inhibitor (PI) GW433908 (908) in antiretroviral therapy-naive HIV-positive patients versus nelfinavir (NFV/Viracept), were presented at the 10th Conference on Retroviruses in Boston.
"Ethanol may have significant effects on human immunodeficiency virus type I (HIV-1) pathogenesis in vivo," according to a recent study from the United States.
Researchers in the United States have developed a program to ensure that people taking part in HIV vaccine studies have the knowledge needed for their ethical inclusion.
Long-term use of highly active antiretroviral therapy (HAART) may be responsible for raising hepatitis C virus (HCV) loads in patients coinfected with human immunodeficiency virus (HIV).
A DNA vaccine containing viral particles prevents many symptoms of infection in primates exposed to the simian version of HIV (SIV), researchers in Maryland report.
Social support may play a small but potentially important role in helping HIV-positive people adhere to the complicated schedules for taking their drug "cocktails" to control the virus that causes AIDS.
Researchers in the United States report disappointing results for an agent with potential for treating HIV-related central nervous system (CNS) morbidity.
Functional magnetic resonance imaging (fMRI) can provide early warning of neurologic morbidity in HIV patients, researchers in the United States report.
Government researchers have established a connection between hepatitis C virus (HCV) infection and liver cancer but not HCV infection and non-Hodgkin lymphoma (NHL) in people with AIDS.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
